Low Energy Therapy to Convert Ventricular Tachycardias

Early Phase 1TerminatedNCT02891863

Boston Scientific Corporation9 enrolled

Overview

The LEVER study is a prospective, unblinded, non-randomized, first in human feasibility study that will assess and characterize early safety and effectiveness of low energy therapies in converting monomorphic ventricular tachycardias (MVTs). Subjects must be already indicated for standard of care VT procedure during which VT is likely to be induced (such as VT testing, VT ablation, VT mapping, or VT risk stratification testing.) The study patches will be applied to the subject's torso, and the patches will be connected to the LEVER Acute Study System. Pacing capture threshold capture may be assessed. If monomorphic VT is induced and reaches at least 170bpm (350ms/cycle), one or more of the low energy therapies will be applied under oversight of the investigator, in an attempt to treat and convert the VT.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Ventricular Tachycardia

Interventions

LEVER Acute Study SystemDEVICE

The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with a history of ventricular tachycardia indicated for ventricular testing procedures that may include VT induction, such as VT testing, VT ablation, VT mapping, or VT risk stratification testing. * Subjects age 18 or above, or of legal age to give written informed consent specific to local laws and requirements * Subjects who, in the opinion of the investigator, are suitable to be enrolled in a clinical study Exclusion Criteria: * Subjects with any comorbidities that, in the opinion of the investigator, would exclude them from standard of care VT testing * Subjects with VT that is known to be focal in nature * Subjects whom the investigator believes are not hemodynamically stable enough to tolerate testing * Subjects of childbearing age who may be pregnant. * Subjects who are unwilling or unable to provide written informed consent. * Subjects with any implanted device that emits electrical energy where either therapy cannot be temporarily disabled, or the subject cannot tolerate temporary disabling of therapy.

Locations (1)

Royal Adelaide Hospital

Adelaide, Australia

Outcomes

Primary Outcomes

System and Procedure Related Adverse Events

All system and procedure-related adverse events through 7 days (-1/+3 days) post-procedure will be collected and tracked.

Time frame: 7 days post-procedure

Conversion Efficacy of Low Energy VT Therapies

Effectiveness of LEVER Acute Study System low energy therapies to convert MVTs will be collected and tracked as an aggregate success rate (%) on a per-attempt basis for each therapy tested.

Time frame: Acute - eg within 5 seconds of test therapy delivery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.